Five Years of Ublituximab in Relapsing Multiple Sclerosis: Additional Results from Open-label Extension of ULTIMATE I and II Studies (P11-1.006)

20250 citationsJournal Article

Authors

To evaluate the long-term clinical efficacy and safety of ublituximab.

Zero hunger

Published in: Neurology

Volume 104, Issue 7_Supplement_1

Field-Weighted Citation Impact: 0.00